The results of the PLATO trial have just been published in the Journal of Clinical Oncology (JCO). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistnt, chemotherapy-naïve, enzalutamide, mCRPC, metastatic, PLATO | Leave a comment »
Below you will find a link to a valuable new review article on ongoing changes in the opportunities for evaluation and management of men with both hormone-sensitive and castration-resistant, metastatic prostate cancer (mHSPC and mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistnt, hormon-sensitive, metastatic, Treatment, type | 1 Comment »
According to information released today by Astellas Pharma and Medivation, the PREVAIL trial of MDV3100 (also now known as enzalutamide) in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) is fully enrolled. .. READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistnt, enzalutamide, mCRPC, MDV3100, metastatic | 6 Comments »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK